Two-year median follow-up data from the Phase 2 RAMP 201 study of avutometinib + defactinib in recurrent LGSOC published. Median DoR 31.1 months, median PFS 12.9 months. Safety consistent. FDA accelerated approval for KRAS-mutated LGSOC already in place.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
